Calico Life Sciences has entered an exclusive licensing agreement with Mabwell Bioscience for 9MW3811, a monoclonal antibody targeting interleukin-11. By inhibiting IL-11 and its downstream signaling pathways, the therapy suppresses inflammation and fibrotic processes. This collaboration focuses on developing treatments for idiopathic pulmonary fibrosis and related age-associated disorders.

Key points

  • Calico licenses 9MW3811, an anti-IL-11 monoclonal antibody, from Mabwell Bioscience for up to $596M.
  • 9MW3811 inhibits IL-11 signaling pathways to reduce inflammatory cascades and collagen deposition in fibrotic tissues.
  • Phase I studies in China and Australia support US IND clearance, paving way for clinical trials in pulmonary fibrosis and age-related disorders.

Why it matters: Targeting IL-11 offers a novel anti-inflammatory and anti-fibrotic strategy that could shift current longevity therapeutic paradigms.

Q&A

  • What is interleukin-11?
  • How does a monoclonal antibody work?
  • Why focus on fibrosis in aging?
Copy link
Facebook X LinkedIn WhatsApp
Share post via...


Read full article

Interleukin-11 in Aging and Longevity

Overview: Interleukin-11 (IL-11) is a signaling protein implicated in inflammation, fibrosis, and tissue repair. While essential for normal physiological processes, dysregulated IL-11 activity contributes to age-associated pathologies like pulmonary fibrosis, liver cirrhosis, and cardiovascular stiffening.

Biological Role:

  • Produced by stromal and epithelial cells in response to injury or stress.
  • Activates IL-11 receptor alpha (IL-11Rα) and gp130, triggering JAK/STAT and MAPK pathways.
  • Promotes fibroblast proliferation and collagen synthesis for wound healing.

IL-11 and Fibrosis:

  • Chronic IL-11 signaling leads to excessive extracellular matrix (ECM) deposition.
  • Fibrotic scarring impairs organ elasticity and function, accelerating age-related decline.
  • Inhibiting IL-11 can reverse or halt fibrosis in preclinical models.

Therapeutic Targeting: Monoclonal antibodies against IL-11—such as 9MW3811—bind the cytokine directly, preventing receptor engagement and downstream signaling. This targeted approach reduces systemic immunosuppression compared to broad anti-inflammatory drugs.

Preclinical Evidence:

  1. Mice treated with anti-IL-11 antibodies show reduced lung collagen content and improved respiratory function.
  2. Blocking IL-11 signaling extends lifespan by preserving muscle function, telomere integrity, and reducing tumor incidence.
  3. Safety profiles in animal studies demonstrate tolerability with minimal off-target effects.

Clinical Development:

  • Phase I trials have assessed safety and pharmacokinetics in healthy volunteers and fibrotic disease patients.
  • Next steps include dose-escalation studies and efficacy trials in idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions.

Implications for Longevity Science:

  • Targeting IL-11 offers a precision medicine strategy to mitigate chronic inflammation and fibrosis—key drivers of aging.
  • Combining anti-IL-11 therapies with lifestyle interventions and regenerative approaches could enhance healthspan.
  • Ongoing research explores IL-11’s role in vascular aging, neuroinflammation, and metabolic disorders.

Understanding IL-11’s dual roles in repair and pathology is vital for developing safe, effective longevity therapeutics aimed at extending healthy human lifespan.